Search research articles
Contact Us
Filters
Showing results (1-10 of 150) with videos related to
Page
of 15
Sort By:
Therapeutic Advances in Urology
|
February 2, 2012
Best practice in the treatment of nonmuscle invasive bladder cancer
Anastasios Anastasiadis, Theo M de Reijke
Critical Reviews in Oncology/Hematology
|
August 23, 2002
EORTC prostate cancer trials: what have we learnt?
Theo M de Reijke, Laurence Collette
Expert Opinion on Emerging Drugs
|
May 8, 2018
Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer
Jasper Crijnen, Theo M De Reijke
Expert Opinion on Pharmacotherapy
|
October 17, 2017
The efficacy of Apaziquone in the treatment of bladder cancer
Francisco Caramés Masana, Theo M de Reijke
Current Opinion in Urology
|
December 13, 2016
Can we improve transurethral resection of the bladder tumour for nonmuscle invasive bladder cancer?
Esmee Iml Liem, Theo M de Reijke
European Urology
|
July 24, 2003
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)
Laurence Collette, Theo M de Reijke, Fritz H Schröder, et al.
Expert Review of Anticancer Therapy
|
August 9, 2017
Improving postoperative radiotherapy following radical prostatectomy
D Lipman, B R Pieters, Theo M De Reijke
Nederlands Tijdschrift Voor Geneeskunde
|
May 5, 2016
[Introduction of PSMA PET requires thorough research]
Theo M de Reijke, Jeroen R J A van Moorselaar
Expert Review of Medical Devices
|
March 9, 2011
GreenLight™ laser in the treatment of lower urinary tract symptoms due to benign prostatic enlargement
Artur A Antoniewicz, Gerasimos Alivizatos, Łukasz Zapała, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
December 2, 2021
['Intelligent case-finding' in prostate cancer: an alternative to population-based screening]
Theo M de Reijke, Ivo G Schoots, Kees van den Berg
Page
of 15
Search research articles
Search
Showing results (1-10 of 150) with videos related to
Sort By:
Page
of 15
Therapeutic Advances in Urology
|
February 2, 2012
Best practice in the treatment of nonmuscle invasive bladder cancer
Anastasios Anastasiadis, Theo M de Reijke
Critical Reviews in Oncology/Hematology
|
August 23, 2002
EORTC prostate cancer trials: what have we learnt?
Theo M de Reijke, Laurence Collette
Expert Opinion on Emerging Drugs
|
May 8, 2018
Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer
Jasper Crijnen, Theo M De Reijke
Expert Opinion on Pharmacotherapy
|
October 17, 2017
The efficacy of Apaziquone in the treatment of bladder cancer
Francisco Caramés Masana, Theo M de Reijke
Current Opinion in Urology
|
December 13, 2016
Can we improve transurethral resection of the bladder tumour for nonmuscle invasive bladder cancer?
Esmee Iml Liem, Theo M de Reijke
European Urology
|
July 24, 2003
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)
Laurence Collette, Theo M de Reijke, Fritz H Schröder, et al.
Expert Review of Anticancer Therapy
|
August 9, 2017
Improving postoperative radiotherapy following radical prostatectomy
D Lipman, B R Pieters, Theo M De Reijke
Nederlands Tijdschrift Voor Geneeskunde
|
May 5, 2016
[Introduction of PSMA PET requires thorough research]
Theo M de Reijke, Jeroen R J A van Moorselaar
Expert Review of Medical Devices
|
March 9, 2011
GreenLight™ laser in the treatment of lower urinary tract symptoms due to benign prostatic enlargement
Artur A Antoniewicz, Gerasimos Alivizatos, Łukasz Zapała, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
December 2, 2021
['Intelligent case-finding' in prostate cancer: an alternative to population-based screening]
Theo M de Reijke, Ivo G Schoots, Kees van den Berg
Page
of 15